GlassScriptPhysician profile
Arif S Syed
NPI 1508068628
$3,285.61
in general payments reported to CMS, 2019-2025
28 companies · $655 in 2025
The $655 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $470 · 2021: $202 · 2022: $317 · 2023: $443 · 2024: $489 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,587.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $400.72 | 2019-2024 | Jot Dx |
| Boston Scientific Corporation | $346.80 | 2019-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $270.42 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.76 | 2019-2025 | Jardiance |
| Pfizer INC. | $239.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $209.75 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $196.86 | 2023-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $171.38 | 2021-2025 | Eliquis, Camzyos |
| Amgen INC. | $157.54 | 2019-2025 | Repatha, Repatha |
| Angiodynamics, INC. | $124.91 | 2022 | |
| Medtronic Vascular, INC. | $123.80 | 2019-2020 | |
| Edwards Lifesciences Corporation | $105.62 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $101.41 | 2019-2022 | |
| Novo Nordisk INC | $69.14 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $65.11 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $53.45 | 2023-2024 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals LP | $51.81 | 2024-2025 | Farxiga, Lokelma |
| Bridgebio Pharma, INC. | $46.31 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $43.87 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $38.27 | 2025 | Onpattro |
| Braemar Manufacturing, LLC | $36.10 | 2019 | |
| Medtronic, INC. | $33.45 | 2022 | |
| Scpharmaceuticals INC. | $30.23 | 2024-2025 | |
| Vifor Pharma, INC. | $28.80 | 2023 | Veltassa |
| Janssen Scientific Affairs, LLC | $22.73 | 2024 | Xarelto |
| Astellas Pharma US INC | $17.81 | 2021 | |
| Biotronik INC. | $16.75 | 2019 | |
| Esperion Therapeutics, INC. | $13.04 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arif Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.